Gyros platform enters leading US Clinical Research Organization
News Mar 16, 2010
Gyros AB, a leader in the automation of miniaturized immunoassays, confirmed today that CEDRA Corporation has become the first North American Clinical Research Organization to incorporate a Gyrolab™ xP workstation into their offering for the biopharmaceutical industry.
The workstation will be used specifically for ligand binding assays at CEDRA’s bioanalytical research laboratory in Austin, Texas. Conventional, multi-step assay formats will be transformed into fully automated, integrated procedures performed at the nanoliter scale thus substantially boosting efficiency and productivity.
William Nowatzke, Ph.D., Director, Ligand Binding Assay Group, CEDRA Corporation explained: “A key driver to our business is the dedication to staying on the forefront of technology. This investment addresses key areas of speed, strength and specificity in instrumentation and represents our dedication to enhancing the capabilities offered to the biopharmaceutical research industry. We are investing in the highest performance system available; its flow-through format shortens analysis time, reduces sample matrix effects and minimizes sample consumption.”
CEDRA joins a steadily increasing number of laboratories in biopharmaceutical, contract research and contract manufacturing companies that have recognized the unique advantages of the Gyros platform. Erik Walldén, CEO at Gyros, added: “We are extremely pleased that leaders in the biotherapeutic industry are acknowledging the significant gains in productivity offered by our immunoassay solution. In fact, we now have a substantial proportion of our clients running multiple systems. Our open technology format enables clients to transfer their established ELISA assays easily and smoothly onto a faster, more efficient platform and to develop and optimize new immunoassays within days rather than weeks.”
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE